Bausch Health (BHC) PT Raised to $24 at BMO Capital on Positive Outcome in Xifaxan Litigation
Tweet Send to a Friend
BMO Capital analyst Gary Nachman raised the price target on Bausch Health Companies (NYSE: BHC) to $24.00 (from $22.00) while ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
